Cure TV

One oncology nurse developed the BARF scale so her young patients could better communicate how they were feeling.

A certain group of patients may not be candidates for common therapies, explained Bijal D. Shah, M.D.

In an interview with CURE, Young explained the importance of whole-person care that included aspects such as yoga and nutrition.

Since these are difficult diseases to treat, research has been quite slow over the last decade or so, but continues to pick up, developing new treatments for patients with these diseases.

A liver cancer specialist can be very beneficial for those diagnosed.

Caring for a young person with cancer can be a challenge, explains Nancy Bell.

When first diagnosed with lung cancer, some doctors told Bonnie J. Addario that there was nothing that they could do for her. Now, 14 years later, she has spent over a decade helping others with the disease through her Bonnie J. Addario Lung Cancer Foundation.

Hear from the winner of our 2018 Extraordinary Healer award.

Chemotherapy and PARP inhibitors may share some side effects, but there are some major differences between the two when it comes to treating ovarian cancer.

Here is what one expert says about the right time to start treating relapsed multiple myeloma.

We spoke to ovarian cancer survivors about their advice for women who are newly diagnosed.

High blood pressure is common in patients with thyroid cancer who are taking Lenvima. Here's what one expert says about managing it.

Should cancers that are not traditionally associated with Lynch syndrome or MSI-H status be tested? This expert thinks so.

CAR-T cell therapy is generating excitement for the treatment of diffuse large B-cell lymphoma, according to an update from the JULIET trial.

There are many exciting advances happening in the field of mantle cell lymphoma.

Here's how one expert decides on the next steps in treatment when a man with prostate cancer has a rising PSA and no visible metastases.

Taylor Bell Duck was only 21 when she was diagnosed with lung cancer, a disease that is often stigmatized.

We've come a long way in determining which patients with prostate cancer to treat, but there is still more work that needs to be done.

Folate receptor alpha was a promising biomarker when it came to treatment with mirvetuximab soravtansine.

Recent research found that patients under 50 were less likely to have a treatment-determining biomarker than their older counterparts.

An expert discusses a trial comparing recombinant interferon alpha-2 with hydroxyurea in patients with myeloproliferative neoplasms (MPNs).

There are some key discussions that men with metastatic prostate cancer should have with their health care providers.

Lung cancer registries, like the Bonnie J. Addario Lung Cancer Foundation's, can be beneficial to patients and researchers.

Researchers should not give up hope in using immunotherapy to treat brain cancers.

As the number of patients and survivors continues to increase, it is important that clinician burnout is handled appropriately, explains Thomas A. Gallo.

It is important that advocacy organizations unify their message, says Mike Crosby, the founder of the Veterans Prostate Cancer Awareness group.

Some immunotherapy drugs target the PD-L1 protein, though this expert says that it is still an imperfect biomarker.

By getting their tumor genetically tested, a patient may find out that they are eligible for certain treatment options.